Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2022 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

3 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean asaravala m[au] (1 results)?
Clinical and economic benefits of lenzilumab plus standard of care compared with standard of care alone for the treatment of hospitalized patients with COVID-19 in the United States from the hospital perspective.
Kilcoyne A, Jordan E, Zhou A, Thomas K, Pepper AN, Chappell D, Amarapala M, Hughes A, Thompson M. Kilcoyne A, et al. Among authors: amarapala m. J Med Econ. 2022 Jan-Dec;25(1):160-171. doi: 10.1080/13696998.2022.2030148. J Med Econ. 2022. PMID: 35037816 Free article.
Clinical and Economic Benefits of Lenzilumab Plus Standard of Care Compared with Standard of Care Alone for the Treatment of Hospitalized Patients with Coronavirus Disease 19 (COVID-19) from the Perspective of National Health Service England.
Kilcoyne A, Jordan E, Thomas K, Pepper AN, Zhou A, Chappell D, Amarapala M, Thériault RK, Thompson M. Kilcoyne A, et al. Among authors: amarapala m. Clinicoecon Outcomes Res. 2022 Apr 14;14:231-247. doi: 10.2147/CEOR.S360741. eCollection 2022. Clinicoecon Outcomes Res. 2022. PMID: 35444434 Free PMC article.
A US payer perspective health economic model assessing value of monitoring disease activity to inform discontinuation and re-initiation of DMT in multiple sclerosis.
Jalaleddini K, Bermel RA, Talente B, Weinstein D, Qureshi F, Rasmussen M, Menon S, Amarapala M, Jordan K, Ghoreyshi A, McCurdy S, Edgeworth M. Jalaleddini K, et al. Among authors: amarapala m. Mult Scler. 2024 Mar;30(3):432-442. doi: 10.1177/13524585241227372. Epub 2024 Feb 19. Mult Scler. 2024. PMID: 38374525